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Abstract 
Releasability of mast cells and basophils to an IgE-dependent stimulus is regulated by extra- and intracellular factors which are only 
partly understood. As gangliosides are known to modulate receptor-dependent processes in various cell types, we have evaluated the 
effect of these molecules on mast cell mediator release. Human skin mast cells and the human mast cell line HMCI were pretreated with 
the gangliosides GM2, GM3 and GDIa as well as with asialo-GM3, heparin and buffer alone (controls). After washing, the cells were 
stimulated with anti-IgE, cah:ium ionophore A 23187, N-FMLP or substance P. All gangliosides but not asialo-GM3 and heparin 
augmented anti-IgE-induced mediator release in a dose-dependent fashion, whereas the release to A 23187, N-FMLP and substance P
remained unaffected. Only sequential but not simultaneous addition of ganglioside and anti-IgE showed an enhancement i  mediator 
release compared to controls. Mediator elease in both ganglioside-pretreated cells and controls was calcium-dependent a d could be 
inhibited by pretreatment of cells with staurosporine or dibutyryl cAMP, indicating an unchanged signal transduction. Gangliosides 
appear to specifically optimize IgE-receptor-ligand interaction and alterations in cellular gangliosides could thus induce enhanced 
releasability as observed in atopics. 
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1. Introduction 
Gangliosides are sialic acid-containing glycosphin- 
golipids consisting of a ]ipophilic ceramide and a hy- 
drophilic oligosaccharide moiety. They are physiological 
components of the outer leaflet of the plasma membrane of 
all vertebrate cells, with the oligosaccharide r st extending 
into the extracellular matrix [ 1]. Cellular gangliosides are 
synthesized, metabolized and catabolized by the individual 
cell itself [2,3]. The membrane pattern is cell-type specific 
[4] but is known to change during growth and neoplastic 
transformation [5,6]. Gangliosides play an important role 
in cell adhesion [7], cell--cell recognition [8], and they 
serve as specific or unspecific receptors for several bacte- 
Abbreviations: GMI, GM2, GM3, GDIa, Lactosylceramide (trivial: 
asialo-GM3), names of individual glycosphingolipids, following the 
nomenclature of Svennerholm [32]; HSA, human serum albumin; MEM, 
minimal essential medium. 
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rial toxins, viruses or hormones [9,10]. In rat basophilic 
leukemia cells, antibodies against a rat-specific ganglioside 
inhibit an IgE receptor-mediated response [ 11,12]. 
In the past, we have shown that gangliosides enhance 
basophil mediator elease stimulated by anti-IgE or aller- 
gen [13]. Since mast cells are the primary effectory cells in 
type I hypersensitivity reactions, the aim of the present 
study was to examine the in vitro influence of gangliosides 
on mediator elease from cutaneous mast cells. 
2. Materials and methods 
Materials. The following reagents were purchased: 
GM2, GM3, GDIa, asialo-GM3 (purity > 98%, endotoxin 
free, Pallmann, Munich, FRG) Pipes, collagenase type l a, 
hyaluronidase type I-S, N-FMLP, substance P, dibutyryl 
cAMP, staurosporine (Sigma, Deisenhofen, FRG), anti-IgE 
(Behring, Marburg, FRG), DNAse I (Boehringer, 
Mannheim, FRG) IgE, A23187 (Calbiochem, Bad Soden, 
FRG), Percoll, 1.124 g /ml  (Seromed, Berlin, FRG), HSA 
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(Pfrimmer, Erlangen, FRG), low molecular weight heparin 
(Sanofi Winthrop, Munich, FRG), MEM/Earle's salts, 
FCS (Gibco, Berlin, FRG), LTC4 EIA (Cayman, Ann 
Arbor, USA), Sep-Pak C18 cartridges (Waters, Milford, 
USA), Silica gel HPTLC plates (Merck, Darmstadt, Ger- 
many) 
Buffers. Pipes A (containing 0.1% HSA), Pipes EDTA 
(Pipes A containing 2% 0.1 M EDTA) and Pipes ACM 
(Pipes A containing 2 mM CaCI 2 and 0.5 mM MgCI 2) 
were used in all experiments ata pH of 7.40. 
Medium. In all experiments, MEM containing 2% FCS, 
1% penicillin and streptomycin, 1% glutamine, 2% MgSO 4 
and 10 /zg/ml DNAse was used. 
Preparation of human skin mast cells. Mast cells from 
normal human breast skin (from plastic surgery) or in 
some experiments from human foreskin were isolated by 
enzymatic dispersion, with slight modification as described 
before [14]. Briefly, skin was cut into small pieces (1-2 
mm2), dispersed in two 1-h cycles with collagenase and 
hyaluronidase (15 mg and 7.5 mg/g tissue respectively, in
2.5 ml medium/g tissue), separated from undissociated 
tissue through filtration with nylon gauze (150 /zm) and 
thereafter washed twice in Pipes A. Viability was checked 
by Trypan blue staining and mast cell purity with Tolui- 
dine blue staining. This procedure yielded 6-8 × 105 mast 
cells/g wet weight tissue with 3-5% mast cells of total 
nucleated cells. 
Mast cell purification. For some experiments, mast cells 
were further purified by Percoll density gradients, as de- 
scribed before [14]. Purities ranged between 50 and 80%, 
but only cell suspensions with mast cell numbers exceed- 
ing 70% were used for further studies. Since the purifica- 
tion could not exclude an effect through contaminating 
cells, additional experiments were performed with the 
human mast cell line HMC1. This cell line shows charac- 
teristics of immature mast cells. It expresses the high 
affinity IgE-receptor in up to 50% of cells and contains 
approx. 10-times less histamine and tryptase than normal 
skin mast cells [15]. 
Passive sensitization with IgE. After isolation and pu- 
rification, cells were washed twice with Pipes A and then 
passively sensitized with IgE (1 /zg/106 cells per ml) at 
room temperature overnight. 
Incubation with glycosphingolipids. Cells in Pipes ACM 
were incubated with GM2, GM3, GDIa, asialo GM3 or 
buffer only (controls) for 30 min at 37°C in a shaking 
water bath (100 /xg glycosphingolipid dissolved in Pipes 
ACM/106 cells per ml). Incubation was stopped by addi- 
tion of 10 ml cold Pipes EDTA (4°C). Cells were then 
washed twice in Pipes A, counted and checked for viability 
and resuspended in Pipes ACM for release studies. 
Ganglioside incorporation study. Following the same 
procedure as described above, HMC1 cells were pretreated 
with GM2 (100 and 300 p,g/106 cells per ml). The 
washed cells were then homogenized and lyophilized. For 
ganglioside analysis, a modified technique as described 
before [16,17] was used. Briefly, after total lipid extrac- 
tion, the dried sample was dissolved in 
diisopropylether/1-butanol d partitioned into two frac- 
tions after mixing with aqueous NaC1 solution. After 
methanolysis of phospholipids, the sample was desalted by 
passing over a Sep-Pak C18 cartridge. The purified gan- 
gliosides were redissoived in chloroform/methanol (1:1 
by vol.), analyzed by thin layer chromatography and quan- 
titatively assessed with a videoscanner (Biotec). 
Incubation with heparin. Cells were treated as described 
for incubation with glycosphingolipids, using equimolar 
concentrations of a low molecular weight heparin instead 
of a glycosphingolipid. 
Mediator elease. Aliquots of 10 4 mast cells in 0.4 ml 
Pipes ACM were challenged in duplicate with identical 
amounts of the following stimuli dissolved in Pipes ACM: 
Anti-IgE (1000, 2000 and 4000 IU/ml, with 0.417 IU 
precipitating 1 ng WHO IgE standard), Ca-ionophore (1 
#M), N-FMLP (1 /xM) or substance P (30 /xM). Sponta- 
neous histamine release was determined by addition of 
Pipes ACM instead of stimuli and ranged from 5 to 10% 
of total histamine content. Total cellular histamine was 
assayed by lysis of aliquots with 2% perchloric acid. After 
a 20 min incubation at 30°C, cells were centrifuged and 
supernatants kept at -80°C for later determination of 
histamine and LTC4. For histamine, results are expressed 
as percent release of total histamine after subtraction of 
spontaneous release. LTC4 is expressed as pg/104 mast 
cells. 
Mediator assays. Histamine was measured by the auto- 
matic fluorometric method described by Siraganian [18]. 
LTC4, which is mainly mast cell-derived in skin disper- 
sates [19], was determined with a commercial EIA kit. 
Cross-reactivity with LTB4 is < 0.01%, according to the 
manufacturer. 
Pharmacological modulation of signal transduction. In 
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Fig. 1. Pretreatment with different gangliosides enhances anti-IgE-media- 
ted (2000 IU/ml) histamine release from skin mast cells in comparison to 
buffer-treated control cells of the same donor (12-14 separate xperi- 
ments for each ganglioside; P < 0.01, analyzed with Wilcoxon's test for 
paired data). 
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Fig. 2. Dose-dependency of GM2-mediated increase inmast cell anti-IgE 
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Fig. 4. Influence of GM2 on anti-IgE-stimulated (2000 IU/ml) LTC4 
release from skin mast cells (5 separate experiments); imilar esults were 
obtained by preincubation with GM3 and GDIa (data not shown). 
order to evaluate the effect of known inhibitors of anti- 
IgE-induced signal transduction [20], cells were pretreated 
in some experiments with staurosporine (1 /zM) or dibu- 
tyryl cAMP (8 mM) for 15 min before addition of anti-IgE. 
The effect of decreased levels of extracellular calcium 
during mediator elease was studied using medium con- 
taining 0.5 and 1 instead of the normally used 2 mM 
CaCI2. 
Statistical analysis. Since the data are not normally 
distributed, medians and ranges are shown instead of means 
and S.E.M.s, and data were analyzed with the Wilcoxon 
test for paired data [21]. 
3. Results 
Preincubation of skin mast cells with GM2, GM3 and 
GDla  significantly enhanced anti-IgE-induced histamine 
release (Fig. 1), whereas addition of gangliosides without 
further stimulation did not affect histamine release (data 
not shown). The augmentation of anti-IgE-induced media- 
tor release by gangliosides was dose-dependent (Fig. 2) 
and could only be observed when cells were preincubated 
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Fig. 3. Comparison fthe effect of GM3 and asialo-GM3 pretreatment o  
anti-lgE (2000 IU/ml) induced histamine r lease (medians of 14 experi- 
ments). 
tion of gangliosides and anti-IgE did not alter mediator 
release compared to controls (data not shown). 
To exclude unspecific structure-dependent ffects, mast 
cells were preincubated with the structural analogue of 
GM3, the neutral glycosphingolipid asialo-GM3. Pretreat- 
ment with asialo-GM3 did not influence mediator elease 
(Fig. 3). An unspecific effect of the negatively charged 
sialic acid in gangliosides was investigated as well. Prein- 
cubation of mast cells with heparin, chosen as an example 
for a structurally different, negatively charged molecule, 
did not affect anti-IgE-induced mediator elease (median 
histamine release 5.2% in controls vs.3.8% after heparin 
pretreatment, n = 5). 
Apart from the preformed mediator histamine, ganglio- 
sides enhanced anti-IgE-stimulated release of the newly 
generated mediator LTC4 as well (Fig. 4). IgE receptor-in- 
dependent mediator elease induced by A 23187, N-FMLP 
or substance P remained unaffected by ganglioside-pre- 
treatment (Table 1). 
In order to investigate whether gangliosides were exert- 
ing their action directly on mast cells or via other cells, 
purified and unpurified mast cells of the same donor were 
compared. Anti-IgE-induced histamine release proved to 
be similar with both preparations (median histamine re- 
lease 18% in unpurified vs. 17% in > 70% purified mast 
cells, n = 4, with an enhancement seen after ganglioside 
pretreatment in all experiments, median 22%) making a 
Table 1 
Histamine release induced by anti-IgE (2000 IU/ml) compared to A 
23187 (1 /xM), N-FMLP (1 /~M) or substance P (30 mM) in GM2 
pretreated cells and controls (medians and range, n = 12 for anti-IgE, 
n = 6 for the other stimuli) 
Stimulus Control GM2 pretreatment 
Anti-IgE 15.3% (5.8-22.5%) 20.7% (8.3-31.0%) 
A23187 25.7% (11.0-31.5%) 26.5% (12.0-31.4%) 
N-FMLP 2.9% (0.0-6.9%) 2.1% (0.0-7.0%) 
Substance P 6.0% (3.6-12.5%) 5.9% (3.9-12.2%) 
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Fig. 5. Effect of extracellular calcium on anti-IgE-stimulated (2000 
IU/ml) histamine release in cells pretreated with GM2 and controls 
(medians of 3 experiments). 
direct interaction of gangliosides and mast cells likely. 
Still, since in Percoll purified mast cells, a possible effect 
of contaminating cells cannot be entirely excluded, addi- 
tional experiments were performed with the human mast 
cell line HMC1. In these cells, gangliosides howed the 
same effect as in skin mast cells (median anti-IgE-induced 
histamine release 37.9% after ganglioside treatment com- 
pared to 28.8% in controls, n = 2). 
To verify the incorporation of the exogenously added 
gangliosides and to estimate alterations in the endogenous 
ganglioside contents, the ganglioside pattern of HMC1 
cells was analyzed in two separate xperiments. Without 
ganglioside pretreatment, 1.59 /xg GM3, 0.29 /xg GM2 
and 0.39/xg GDla per mg protein were found. When cells 
were preincubated with 100 /zg GM2/106 cells per ml 
which is the concentration normally used in release xperi- 
ments, 0.59 /zg GM2/  mg protein were detected. After 
preincubation with 300 /xg GM2/106 cells per ml, gan- 
glioside contents increased to 0.96 /zg GM2/mg protein. 
In order to investigate whether ganglioside-modulated 
mediator release involved physiological signal transduction 
pathways, experiments in calcium-depleted buffer and with 
staurosporine or dibutyryl cAMP-pretreated cells were per- 
formed. Anti-IgE-induced histamine release was shown to 
be calcium dependent in both controls and ganglioside-pre- 
treated cells (Fig. 5). Staurosporine, an inhibitor of several 
protein kinases including protein kinase C, and dibutyryl 
cAMP, an activator of protein kinase A, showed a compa- 
rable inhibitory effect on the response to anti-IgE in 
Table 2 
Inhibitory effect of dibutyryl cAMP (d-cAMP, 8 raM) and staurosporine 
(stauro, 1 /xM) on anti-IgE (2000 IU/ml) stimulated histamine release in 
GM3-pretreated cells and controls (medians and range of 8 experiments) 
Stimulus Control GM3 pretreatment 
Anti-IgE 15.6% (10.9-27.5%) 22.7% (14.6-32.0%) 
Anti-IgE+d-cAMP 8.7% (2.1-25.0%) 10.7% (7.0-28.0%) 
Anti-IgE+ stauro 12 3% (6.3-18.3%) 13.0% (6.0-22.0%) 
ganglioside pretreated cells as well as in controls (Table 
2). 
4. Discussion 
Mast cell and basophil releasability is defined as the 
ability to secrete histamine in response to a given IgE-re- 
ceptor-dependent stimulus [22]. This releasability is known 
to show a high variance, is generally enhanced in allergic 
patients, but does not correlate with the number of IgE 
receptors [23]. Factors regulating this process are not well 
understood. The present study represents an attempt o 
elucidate possible mechanisms of changes in mast cell 
releasability at the cellular level by investigating the role 
of gangliosides as constituents of the cell membrane. Gan- 
gliosides are expressed on the cell surface in an enzymati- 
cally controlled pattern which can vary by more than 
10-fold under changing conditions such as differentiation 
or neoplastic growth [24,25]. In the present study, en- 
hanced mast cell releasability was already seen with a 
two-fold increase in membrane-bound ganglioside GM2. 
This alteration in ganglioside content appears thus to be of 
a magnitude which is physiologically possible. Intra- 
cellular changes in the expression of membrane ganglio- 
sides might therefore play a role in the regulation of 
releasability in vivo. The enhancement of anti-IgE-induced 
histamine release is in the range of 15% median histamine 
release before, compared to 21% after, ganglioside pre- 
treatment. Although these differences may appear low, this 
represents a 30% increase of histamine release which 
could be biologically relevant since similar differences 
were observed in anti-IgE-induced histamine release be- 
tween normal controls and allergic asthmatics (median 
histamine release 20% vs. 26% [13]). 
This ganglioside-induced effect seems to be specific for 
IgE-receptor-dependent mediator release since the re- 
sponse to A 23187, N-FMLP and substance P remained 
unaffected. The latter stimuli were chosen since they in- 
duce mediator release through mechanisms independent of 
the IgE receptor. Substance P is a neuropeptide and a 
physiological stimulus for skin mast cell mediator elease 
[26]. N-FMLP is a receptor-dependent stimulus inducing 
substantial histamine release in basophils, whereas in mast 
cells it exerts only a weak action. Thus, N-FMLP-induced 
histamine release in lung mast cells is less than 3-5% [27] 
and in human skin mast cells it is normally insignificant 
[15], which is in line with the present results. The calcium 
ionophore A 23187 was chosen as an example for a 
receptor-independent, u physiological stimulus. 
A specific enhancement of IgE-receptor-dependent me-
diator release by gangliosides, as reported here, is consis- 
tent with our own previous observations in basophils [13]. 
The data stand, however, in contrast o the findings of 
Jensen et al. [28,29], who reported an inhibition of his- 
tamine release in basophils and rat mast cells by ganglio- 
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sides. This divergence of data may be due to the fact that 
our experiments were performed at physiological pH, 
whereas Jensen et al. incubated the cells at pH 5.6 [28] 
which alters the physico-chemical behaviour of the acidic 
gangliosides. 
The present data also ,;how that the augmentation of
IgE-receptor-dependent mediator release is specific for 
gangliosides. Neither the neutral structural analogue asialo- 
GM3 nor heparin as an example for a negatively charged 
but structurally different molecule modulated mediator re- 
lease. The enhanced response to anti-IgE in ganglioside- 
pretreated cells affected both the release of histamine 
which is stored in a prefolxned state in intracellular gran- 
ules, and of LTC4, which is produced de novo from 
arachidonic acid in a 5-1ipoxygenase-dependent pathway. 
Mast cell mediator elease after ganglioside pretreat- 
ment seemed to follow the physiological signal transduc- 
tion pathway in that it was calcium-dependent a d could 
be inhibited by staurosporine and dibutyryl cAMP. 
Regarding these findings and the fact that both pre- 
formed and non-preformed mediator release is affected, it 
seems likely that gangliosides exert heir action either at an 
early level of signal tran,;duction or at the level of the 
plasma membrane through an interaction with exogenous 
ligands. In concordance with the latter concept, membrane 
gangliosides have been shown to modulate processes of 
cell adhesion [7] and the reception of extracellular signals 
[8]. Since gangliosides have a high lateral diffusion capac- 
ity [30], they may be able to transport unspecifically-bound 
ligands laterally across the cell membrane. This mecha- 
nism has been shown for enkephalins [31] which are bound 
by gangliosides three orders of magnitude weaker than by 
the opiate receptor, but the concentration f gangliosides at 
the synaptic membrane is 110 6 times higher than that of the 
specific receptor. Thus, a primary encounter of an 
enkephalin molecule by random collision with a ganglio- 
side is more likely than with its specific receptor. By 
lateral diffusion the ganglioside-bound enkephalin will then 
encounter its specific receptor and will be transferred due 
to higher affinity. Changes in synaptic ganglioside xpres- 
sion are therefore assumed to be able to regulate the 
enkephalin response rate. 
A similar interaction of gangliosides with anti-IgE seems 
feasible. Since the ganglioside membrane content is enzy- 
matically regulated by the individual cell, gangliosides 
might be an intracellular :factor in the regulation of mast 
cell releasability. 
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